SCHEMBL2950290

SCHEMBL2950290

Cn1cc(CN2CC(Nc3nccc(N4CCCCCC4)n3)C2)c2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.57
HRH4 Q9H3N8 4/20 0.46
LMNA P02545 2/20 0.44
GLA P06280 1/20 0.44
MAPK8 P45983 3/20 0.42
PDE2A O00408 1/20 0.42
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
MAPK9 P45984 2/20 0.41
CCNE1 P24864 1/20 0.40
CDK2 P24941 1/20 0.40
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
CCNB3 Q8WWL7 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1090977 0.83 CXCR4 (0.62) CXCR4HRH4MAPK8TSHRMAPK9
SCHEMBL1091394 0.82 CXCR4 (0.63) CXCR4HRH4MAPK8MAPK9CCNE1
SCHEMBL1091085 0.81 CXCR4 (0.59) CXCR4HRH4LMNAMAPK8ALDH1A1
SCHEMBL1090316 0.80 CXCR4 (0.56) CXCR4HRH4LMNAMAPK8ALDH1A1
SCHEMBL1092284 0.80 CXCR4 (0.58) CXCR4LMNAALDH1A1TSHR
SCHEMBL1090884 0.80 CXCR4 (0.60) CXCR4HRH4ALDH1A1TSHR
SCHEMBL1089573 0.80 CXCR4 (0.85) CXCR4HRH4
SCHEMBL1089190 0.79 CXCR4 (0.59) CXCR4HRH4MAPK8MAPK9
SCHEMBL1090262 0.78 CXCR4 (0.66) CXCR4HRH4LMNAMAPK8MAPK9
SCHEMBL1090724 0.78 CXCR4 (0.60) CXCR4HRH4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CXCR4 1/4885HRH4 130/4885LMNA 3658/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885HRH4 130/4885LMNA 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.